JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.


Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 25 02 2019
revised: 26 03 2020
accepted: 07 06 2020
pubmed: 13 7 2020
medline: 30 10 2020
entrez: 13 7 2020
Statut: ppublish

Résumé

JPH203 is a novel anti-cancer drug targeting L-type amino acid transporter 1 (LAT1), which plays a primary role in the uptake of essential amino acids in tumor cells. Although a co-incubation inhibitory effect of JPH203 has been shown in a conventional uptake assay, its preincubation inhibitory effects have remained undetermined. Therefore, we aimed to characterize the preincubation inhibitory effects of JPH203 on LAT1 function using leucine uptake assays in LAT1-positive human colon cancer HT-29 cells. Preincubation of the cells with JPH203 (0.3 μM for 120 min) decreased the activity level to 30% of that in dimethylsulfoxide-treated cells. Similarly, in time-dependency analysis, preincubation of HT-29 cells with 10 μM JPH203 for 30, 60, and 120 min decreased the leucine uptake activity (42%, 32%, and 28% of that in control cells, respectively). Furthermore, the IC

Identifiants

pubmed: 32653341
pii: S1347-8613(20)30063-3
doi: 10.1016/j.jphs.2020.06.006
pii:
doi:

Substances chimiques

2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid 0
Antineoplastic Agents 0
Benzoxazoles 0
Large Neutral Amino Acid-Transporter 1 0
SLC7A5 protein, human 0
Tyrosine 42HK56048U
Leucine GMW67QNF9C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-22

Informations de copyright

Copyright © 2020 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors indicated no potential conflicts of interest.

Auteurs

Kentaro Okunushi (K)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan.

Tomomi Furihata (T)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Hanae Morio (H)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yasuhide Muto (Y)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Kosuke Higuchi (K)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

Meika Kaneko (M)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yusuke Otsuka (Y)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yuta Ohno (Y)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yasuhiro Watanabe (Y)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yoshie Reien (Y)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Kiyoshi Nakagawa (K)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Shinichi Sakamoto (S)

Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

Hidefumi Wakashin (H)

Department of Regulatory Physiology, Dokkyo Medical University School of Medicine, Tochigi, Japan.

Naoki Shimojo (N)

Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan.

Naohiko Anzai (N)

Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Tochigi, Japan. Electronic address: anzai@chiba-u.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH